Phillips-Medisize Expands Kontiolahti, Finland Site
Hudson, WI – February 13, 2013 – Today, Phillips-Medisize Corporation announced a 60,000 square foot (6,000 square meter) expansion to their Kontiolahti, Finland site. This site focuses on the production of complex drug delivery devices such as inhalers, injection pens and safety syringes. This state-of-the-art facility manufactures various products from multi component drug delivery devices in prototype form to finished drug delivery devices in a high speed automated production environment.
This expansion was driven by new opportunities that Phillips-Medisize has been awarded over the past 12 months, as well as, to support increased global demand for devices with precise dosage drug delivery requirements that the company currently manufactures at the Kontiolahti site.
This capacity addition should be online by August 2013 and will increase molding and assembly capabilities at the site. Staffing will also be increased by over 15% during the next two years. Today, 336 professionals are focused on meeting the needs of drug delivery device customers around the world.
The combination of a stable and experienced medical work force, extensive in-house tool making, state-of-the-art metrology, modern cleanrooms, injection molding and high volume automated assembly capabilities underlines the company's mission to provide leading edge technologies and facilities coupled with the most creative people to support our OEM customers.
Commenting on this plant expansion, Matt Jennings, President and CEO of Phillips-Medisize Corporation said, "This plant expansion is in keeping with our global strategy of offering design and development services and associated manufacturing processes for our medical customers. We support this strategy by investing in our people, processes and facilities to assure we can meet the quality, service and performance expectations of our customers. Although a portion of this new capacity will be taken up by recent wins, we did also plan for future customer growth requirements in this expansion."
About Phillips-Medisize Corporation
Phillips-Medisize is a leading global outsource provider of design and manufacturing services to the medical device and diagnostics, drug delivery and commercial markets. The company has annual sales of just under $500 million with 75% of the total revenue coming from drug delivery, medical device and diagnostic products such as: disposable insulin pens, glucose meters, specialty inhalation drug delivery devices, single use surgical devices and consumable diagnostic components.
Phillips-Medisize Corporation features a list of blue chip medical device, pharmaceutical and commercial customers. The company partners with its customers to provide design and development services which accelerate speed to market of innovative products and then works with its customers to deploy advanced automated assembly and quality control technologies which reduce manufacturing cost while improving quality. The company’s core advantage is the knowledge of its people to integrate design, molding, and automation to drive low cost and high quality manufacturing solutions.
Phillips-Medisize Corporation is headquartered in Hudson, WI, and employs over 2,100 people in 12 locations throughout the United States, Europe and China. The company also has design centers in Wisconsin, California, and The Netherlands.
For more information, contact: